drugset / Trial / NCT00400348
Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy, limited pharmacokinetics (PK), and safety of 1,000 mg of Panzem® NCD administered orally four times a day to patients with recurrent or resistant epithelial ovarian cancer.
Timeline
- Start
- 2006-10
- Primary completion
- 2008-08
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panzem | Unknown | 1000 mg | Oral |